Abstract
Cardiovascular (CV) risk factors often coexist - most of patients with arterial hypertension have also hypercholesterolemia which doubles their risk of cardiovascular events. Accordingly, European guidelines for prevention and treatment of CV diseases recommend pharmacotherapy targeted at multiple risk factors.
A brand new triple combination with great potential to improve patient adherence is the fixed combination of atorvastatin, perindopril and amlodipine (Lipertance). The combination of amlodipine and perindopril is characterised not only by very good antihypertensive efficacy (complementary mechanism of action), but also by cardioprotectivity and nephroprotectivity, it is well tolerated and metabolically beneficial.
Adding atorvastatin to this combination in the ASCOT-LLA trial led to a significant reduction of nonfatal myocardial infarction, death from coronary heart disease, all CV events as well as revascularization procedures which was explained by synergic interaction between lipid-lowering and antihypertensive regimens. Fixed triple combination of atorvastatin, perindopril and amlodipine appears thus very promising in improvement of prognosis of patients in primary as well as secondary prevention of CV disease.